Sort   by:  
 Page size 
ProteomicsIntegrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
Clear cell renal cell carcinoma (ccRCC) is the dominant subtype of renal cancer. With currently available therapies, cure of advanced and metastatic ccRCC is achieved only in rare cases. Here, we developed a workflow integrating different -omics technologies to identify ccRCC-specific HLA-presented ...
ORGANISM(S): Homo sapiens (Human) 
2020-04-03 | PXD017149 | Pride
Peptide vaccine Ccrcc Renal cell carcinoma Ligandomics Immunotherapy Cancer vaccine Kidney cancer Hla peptidomie 
UnknownIntegrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Not available
S-EPMC7106651 | biostudies-literature
UnknownHLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
Not available
S-EPMC4910750 | biostudies-literature
UnknownPitfalls in HLA Ligandomics-How to Catch a Li(e)gand.
Not available
S-EPMC8313844 | biostudies-literature
Unknown'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
Not available
S-EPMC5654951 | biostudies-literature
ProteomicsMulti-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
HLA class I ligandome dataset obtained from hepatocellular carcinoma (HCC) as well as corresponding adjacent benign liver tissue (n=16) characterizing respective HLA immunoprecipitates. Additionally, from a subset of the mentioned HCC/ adjacent benign liver samples datasets gained from shotgun prote...
ORGANISM(S): Homo sapiens (Human) 
2019-05-06 | PXD013057 | Pride
Hla Hla ligandomics Multi-omics Peptide prediction Mass spectrometry Personalized medicine Immunoinformatics Next-generation sequencing Immunotherapy Hepatocellular carcinoma Neoantigen Liver cancer 
ProteomicsImmunopeptidome of Renal Cell Carcinoma (RCC) and Bladder Cancer (BC) Patient-Derived Tumor Organoids (PDTOs)
Patient-Derived Tumor Organoids (PDTOs) have emerged as physiologically relevant systems, retaining genomic and phenotypic features of patient tumors and enabling drug response prediction. Here, we established a patient-specific pipeline to evaluate precision immunotherapy in Renal Cell Carcinoma (R...
ORGANISM(S): Homo sapiens (Human) 
2026-08-24 | PXD068567 | Pride
Ligandome Pdtos Mhc Hla-i Dda Immunopeptidomics Hla Immunopeptidome Ligandomics Patient-derived tumor organoids Renal cell carcinoma Rcc Timstof scp Mhc-i Bladder cancer 
UnknownThe regulatory role of hepatoma-derived growth factor as an angiogenic factor in the eye.
Not available
S-EPMC4842004 | biostudies-literature
ProteomicsImmunopeptidomics by use of a microfluidics chip.
A microfluidics technology was implemented to the immunoaffinity purification process of MHC peptides in Ligandomics/Immunopeptidomics. The thus purified HLA peptides were analysed by LCMS with the nanoElute LC and TimsTOF Pro Mass Spectrometer from Bruker. The aim of the microfluidics implementatio...
ORGANISM(S): Homo sapiens (Human) 
2022-02-17 | PXD022194 | Pride
Human Bladder cancer Ligandome Patient derived organoid Hla-i Renal cell carcinoma Microfluidics Ovarian cancer Immunopeptidome Jy cell line Chip Mhc-i Rcc 
ProteomicsImmunopeptidomics of Acute Myeloid Leukemia (AML) Blast cells after Therapy-Induced Senescence (TIS) with Cytarabine.
Resistance or relapse upon chemotherapy are major determinants of treatment failure in acute myeloid leukemia (AML). Therapy-induced senescence (TIS) is a potential outcome of chemotherapy, but its immunological consequences in AML remain unclear. We show that ex-vivo chemotherapy induces senescence...
ORGANISM(S): Homo sapiens (Human) 
2026-08-13 | PXD068731 | Pride
Immunopeptidomics Therapy-induced senescence Tis Hla Ligandome Mhc Cytarabine Ligandomics Immunopeptidome Timstof scp Acute myeloid leukemia Aml 
Sort   by:  
 Page size